Lung cancer (LC) represents the second most diagnosed tumor and the malignancy with the
highest mortality rate. In recent years, tremendous progress has been made in the treatment …

Introduction: In non-small-cell lung cancer (NSCLC) the recent introduction of
immunotherapy in daily clinical practice produced a wave of enthusiasm, however, this was …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

Lung cancer is the leading cause of cancer-related death worldwide, with a poor prognosis.
Despite aggressive treatment, progression-free survival (PFS) and overall survival are …

Immunotherapy with PD‐1 and PD‐L1 inhibitors has revolutionized the treatment for patients
with NSCLC the last years with increased overall survival and in particular increased …

Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically
divided into two major histological subtypes: non-small-cell lung cancer (NSCLC) and small …

Lung cancer is the most common cancer and leading cause of cancer death. While targeted
therapies have redefined treatment options for non-small cell lung carcinoma (NSCLC) with …

Over the last decade, the use of targeted therapies and immune therapies led to drastic
changes in the management lung cancer and translated to improved survival outcomes. This …

Lung cancer is rich in molecular complexities and driven by different abnormal molecular
pathways. Personalised medicine has begun to bring new hope for the treatment of patients …

Immunotherapies are now considered as a pillar of non-small-cell lung cancer treatment.
The main targets of immune-checkpoint inhibitors (ICI) are programmed cell death …